AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Valar Labs Scores a U.S. First With Breakthrough Status for Its AI Bladder Cancer Test
Valar Labs has received breakthrough device designation for its Vesta bladder cancer risk test, positioning the company as an early mover in AI-enabled urologic risk stratification. The designation could help speed development, but it also raises expectations for clinical utility and reimbursement relevance.
FDA Grants Breakthrough Status to a Generative AI Radiology Model, Raising the Bar for Imaging AI
A generative AI radiology model has received FDA Breakthrough Device designation, underscoring how quickly advanced imaging AI is moving into regulated clinical territory. The designation does not equal approval, but it signals that the agency sees meaningful potential to improve diagnosis or treatment.
Airway Medical’s Drug-Coated Balloon Wins FDA Breakthrough Designation
The FDA has granted breakthrough device designation to Airway Medical’s pulmonary drug-coated balloon, giving the company a potentially faster path through development. The designation also highlights continued interest in interventional technologies for challenging pulmonary conditions.
Orchestra BioMed Gets Another FDA Breakthrough Device Tag for AVIM Therapy
The FDA granted Orchestra BioMed an additional Breakthrough Device Designation for AVIM therapy, extending regulatory momentum for the cardiovascular technology. The designation may help streamline development and communication with regulators, but it does not substitute for clinical proof.
CorTec’s breakthrough designation shows neurotech is moving from concept toward reimbursable care
CorTec has received FDA breakthrough device designation for a brain-computer interface aimed at stroke rehabilitation, adding momentum to a neurotechnology field trying to translate experimental promise into clinical pathways. The designation does not guarantee approval, but it signals that regulators see plausible potential in devices addressing major unmet neurological needs.
Breakthrough Status for MeMed BV Flex Signals Demand for Faster Infection Decision Tools
The FDA has granted breakthrough device designation to MeMed BV Flex, highlighting ongoing demand for diagnostics that can improve infection assessment and treatment decisions. The designation gives the company regulatory momentum in a category where speed, accuracy, and antibiotic stewardship all carry high clinical value.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.